

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>The Hydration Pharmaceuticals Company Limited</b>
<b>ACN</b>	<b>620 385 677</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Margaret Hardin
<b>Date of last notice</b>	9 March 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Margaret L Hardin as trustee for Margaret L Hardin Revocable 2013 Trust  (Margaret Hardin has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)
<b>Date of change</b>	2 October 2023
<b>No. of securities held prior to change</b>  Margaret L Hardin  Margaret L Hardin as trustee for Margaret L Hardin Revocable 2013 Trust*  *(Margaret Hardin has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)	53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027  39,130 Fully Paid Ordinary Shares
<b>Class</b>	1. Fully Paid Ordinary Shares 2. Unlisted Options

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	<ol style="list-style-type: none"> <li>333,333 Fully Paid Ordinary Shares</li> <li>166,667 Unlisted Options</li> </ol>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> <li>\$0.045 per fully paid ordinary share subscribed for as sub-underwriter under the Company's Entitlement Offer.</li> <li>Nil consideration – one attaching option for every two shares subscribed for as sub-underwriter under the Company's Entitlement Offer.</li> </ol>
<b>No. of securities held after change</b>  Margaret L Hardin  Margaret L Hardin as trustee for Margaret L Hardin Revocable 2013 Trust*  *(Margaret Hardin has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)	53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027  372,463 Fully Paid Ordinary Shares  166,667 unlisted options exercisable at \$0.07 per option and expiring on 31 December 2025.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the pro rata, non-renounceable entitlement offer announced to the market on 3 August 2023 in the capacity as sub-underwriter. See prospectus dated 4 August 2023 and amended Appendix 3B dated 30 August 2023 for further details.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	

+ See chapter 19 for defined terms.

<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>The Hydration Pharmaceuticals Company Limited</b>
<b>ACN</b>	<b>620 385 677</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Adem Karafili
<b>Date of last notice</b>	14 June 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Ankara Holdings Pty Ltd <The Ankara Family Trust>*  (Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)
<b>Date of change</b>	1. 2 October 2023 2. 2 October 2023 3. 8 August 2023
<b>No. of securities held prior to change</b>  Ankara Holdings Pty Ltd <The Ankara Family Trust>*	907,289 fully paid ordinary shares  653,128 fully paid ordinary shares subject to escrow until 13/12/2023  74,739 unlisted options with an exercise price of \$0.45 expiring on 13 January 2029 subject to escrow until 13/12/23

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<p>Ankara Holdings Pty Ltd ATF A&amp;N Karafili Family Trust*</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p>	<p>The following unlisted options to acquire ordinary shares, all of which are subject to ASX escrow until 9 December 2023:</p> <ul style="list-style-type: none"> <li>• 100,000 unlisted options with an exercise price of \$0.29 expiring on 31 August 2024;</li> <li>• 800,000 unlisted options with an exercise price of \$0.20 expiring on 31 August 2024; and</li> <li>• 1,000,000 unlisted options with an exercise price of \$0.29 expiring on 1 December 2026.</li> </ul> <p>53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027</p>
<p><b>Class</b></p>	<ol style="list-style-type: none"> <li>1. Fully Paid Ordinary Shares</li> <li>2. Unlisted Options</li> <li>3. Fully Paid Ordinary Shares</li> </ol>
<p><b>Number acquired</b></p>	<ol style="list-style-type: none"> <li>1. 1,000,000 Fully Paid Ordinary Shares</li> <li>2. 500,000 Unlisted Options</li> <li>3. 1,972 Fully Paid Ordinary Shares, all of which are escrowed until 13 December 2023</li> </ol>
<p><b>Number disposed</b></p>	<p>Nil</p>
<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation</p>	<ol style="list-style-type: none"> <li>1. \$0.045 per fully paid ordinary share subscribed for as sub-underwriter under the Company's Entitlement Offer</li> <li>2. Nil consideration - one attaching option for every two shares subscribed for as sub-underwriter under the Company's Entitlement Offer</li> <li>3. \$0.2146 per fully paid ordinary share</li> </ol>
<p><b>No. of securities held after change</b></p> <p>Ankara Holdings Pty Ltd &lt;The Ankara Family Trust&gt;*</p>	<p>1,907,289 fully paid ordinary shares</p> <p>655,100 fully paid ordinary shares subject to escrow until 13/12/2023</p> <p>74,739 unlisted options with an exercise price of \$0.45 expiring on 13 January 2029 subject</p>

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<p>Ankara Holdings Pty Ltd ATF A&amp;N Karafili Family Trust*</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p>	<p>to escrow until 13/12/23</p> <p>500,000 unlisted options exercisable at \$0.07 per option and expiring on 31 December 2025.</p> <p>The following unlisted options to acquire ordinary shares, all of which are subject to ASX escrow until 9 December 2023:</p> <ul style="list-style-type: none"> <li>• 100,000 unlisted options with an exercise price of \$0.29 expiring on 31 August 2024;</li> <li>• 800,000 unlisted options with an exercise price of \$0.20 expiring on 31 August 2024; and</li> <li>• 1,000,000 unlisted options with an exercise price of \$0.29 expiring on 1 December 2026.</li> </ul> <p>53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027</p>
<p><b>Nature of change</b></p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<ol style="list-style-type: none"> <li>1. Participation in the pro rata, non-renounceable entitlement offer announced to the market on 3 August 2023 in the capacity as sub-underwriter. See prospectus dated 4 August 2023 and amended Appendix 3B dated 30 August 2023 for further details.</li> <li>2. Participation in the pro rata, non-renounceable entitlement offer announced to the market on 3 August 2023 in the capacity as sub-underwriter. See prospectus dated 4 August 2023 and amended Appendix 3B dated 30 August 2023 for further details.</li> <li>3. Issue of shares subject to mandatory escrow on rectification of conversion of pre-IPO convertible notes as announced to ASX on 9 August 2023.</li> </ol>

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

+ See chapter 19 for defined terms.

Appendix 3Y  
Change of Director's Interest Notice

---

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.